Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Integra LifeSciences (NASDAQ:IART) announced its earnings results on Wednesday. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08, FiscalAI reports. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences updated its Q3 2026 guidance to 0.530-0.610 EPS and its FY 2026 guidance to 2.400-2.500 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Second-quarter execution improved: Revenue reached $419 million, up 0.7% organically, while adjusted EPS rose 24% year over year to $0.56 and exceeded the company’s guidance range. Gross margin expanded 60 basis points and adjusted EBITDA margin increased 160 basis points, supported by manufacturing efficiencies, lower remediation spending, and cost initiatives.
• Integra reaffirmed its 2026 organic revenue growth outlook of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, but lowered reported revenue expectations to $1.654-$1.695 billion because of foreign-ex exchange impacts. Potentially higher second-half interest expense from a planned refinancing is expected to be offset by tariff benefits and additional cost savings.
• Supply and product-relaunch milestones advanced: Manufacturing restarted at the Braintree facility, with inventory being built for a phased fourth-quarter SurgiMend relaunch. PriMatrix revenue has recovered to slightly above 50% of pre-recall levels, while DuraSorb continues to deliver double-digit growth.
• The company expects longer-term growth from potential PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction, with SurgiMend targeted for earlier 2027 and DuraSorb later in 2027, subject to FDA inspections and approval.
• Tissue Reconstruction revenue declined 2% organically in the quarter, with Integra Skin facing a difficult comparison and MicroMatrix pressured by new competitors. ENT revenue also fell by low single digits as sinus-balloon reimbursement pressure outweighed growth in MicroFrance instruments.

Integra LifeSciences Stock Performance

NASDAQ:IART traded up $1.28 during trading hours on Thursday, reaching $17.77. 561,539 shares of the stock were exchanged, compared to its average volume of 905,364. The stock has a market capitalization of $1.38 billion, a P/E ratio of -2.75, a P/E/G ratio of 1.37 and a beta of 1.22. The firm has a 50 day simple moving average of $17.63 and a 200-day simple moving average of $13.42. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49.

Analyst Ratings Changes

Several equities research analysts have issued reports on IART shares. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday. Truist Financial raised their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Citigroup reaffirmed a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday. They set a “neutral” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $18.86.

Hedge Funds Weigh In On Integra LifeSciences

Several large investors have recently added to or reduced their stakes in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences during the 1st quarter valued at about $277,000. Goldman Sachs Group Inc. raised its stake in Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after acquiring an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Integra LifeSciences in the second quarter valued at approximately $491,000. 84.78% of the stock is currently owned by institutional investors.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported second-quarter earnings of $0.56 per share, above the $0.48 analyst consensus and up from $0.45 a year earlier. Revenue of $418.8 million was essentially in line with estimates. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo raised its price target for IART from $15 to $18. Although the firm maintained an “equal weight” rating, the higher target reflects improved valuation support and leaves modest additional upside from recent trading levels. Wells Fargo Raises Integra LifeSciences Price Target
• Positive Sentiment: Technical screens identified Integra as a potential breakout stock trading near its 52-week high, suggesting continued momentum could attract additional buyers. Stocks Showing Breakout Potential
• Neutral Sentiment: Management guided to third-quarter EPS of $0.53-$0.61 and revenue of $410 million-$425 million, broadly consistent with Wall Street expectations. Full-year EPS guidance of $2.40-$2.50 also brackets the $2.45 consensus, limiting the potential for a major estimate-driven re-rating. Integra LifeSciences Second-Quarter Results
• Neutral Sentiment: UBS began coverage of Integra, adding fresh institutional research coverage; the available report does not specify its rating or price target. UBS Begins Coverage on Integra LifeSciences

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.